Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
August 22, 2013

Catabasis begins Phase II trial of CAT-2003 for hypertriglyceridemia, hypercholesterolemia

Catabasis Pharmaceuticals has begun a PATHWAYS I, Phase II trial of CAT-2003, a new chemical entity that is a SMART Linker conjugate, in patients with hypertriglyceridemia and hypercholesterolemia.

Catabasis Pharmaceuticals has begun a PATHWAYS I, Phase II trial of CAT-2003, a new chemical entity that is a SMART Linker conjugate, in patients with hypertriglyceridemia and hypercholesterolemia.

The trial will assess the safety, tolerability and efficacy of CAT-2003 in patients with hypertriglyceridemia and in combination with statins in patients with hypercholesterolemia.

Catabasis chief medical officer Dr Joanne Donovan said that the positive Phase I data showed that CAT-2003 significantly reduced fasting and post-prandial triglyceride levels in healthy individuals and produced an improvement in lipid biomarkers such as LDL-C, ApoB and PCSK9.

"As a result of the inhibition of PCSK9 production we have observed with CAT-2003, we may see a synergistic effect with statins in lowering lipids such as LDL."

"Because of these promising results, we are advancing CAT-2003 into Phase 2 to evaluate the drug’s effects in patients with hypertriglyceridemia and hypercholesterolemia," Donovan added.

A total of 72 patients with moderate hypertriglyceridemia will be randomised with one of three doses of CAT-2003 or placebo for a period four weeks in the first arm of the double-blind, placebo-controlled Phase II study.

Fasting triglycerides and non-HDL-C in the patients will be measured and compared to baseline.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

A total of 24 patients with hypercholesterolemia on statins will be administered with either a specified dose of CAT-2003 or placebo once per day for four weeks in the second arm, in which fasting LDL-C levels will be assessed.

Catabasis co-founder and chief scientific officer Dr Michael Jirousek noted that CAT-2003 acts through the intracellular targeting of multiple nodes in the lipid synthesis pathway.

"One arm of this study will focus on evaluating the effect of CAT-2003 on lipid levels in combination with statins in patients with hypercholesterolemia," Jirousek added.

"As a result of the inhibition of PCSK9 production we have observed with CAT-2003, we may see a synergistic effect with statins in lowering lipids such as LDL."

The company expects top line data in the fourth quarter of 2013.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU